Cargando…
Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
Background: Intracranial hemorrhage (ICH) is associated with high mortality and morbidity, especially in patients under anticoagulative treatment. Andexanet alfa (AA) is a modified recombinant form of human factor Xa (FXa) developed for reversal of FXa-inhibitors, e.g., in the event of ICH, but expe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224862/ https://www.ncbi.nlm.nih.gov/pubmed/35743469 http://dx.doi.org/10.3390/jcm11123399 |
_version_ | 1784733473028702208 |
---|---|
author | Rauch, Sebastian Müller, Hans-Peter Dreyhaupt, Jens Ludolph, Albert C. Kassubek, Jan Althaus, Katharina |
author_facet | Rauch, Sebastian Müller, Hans-Peter Dreyhaupt, Jens Ludolph, Albert C. Kassubek, Jan Althaus, Katharina |
author_sort | Rauch, Sebastian |
collection | PubMed |
description | Background: Intracranial hemorrhage (ICH) is associated with high mortality and morbidity, especially in patients under anticoagulative treatment. Andexanet alfa (AA) is a modified recombinant form of human factor Xa (FXa) developed for reversal of FXa-inhibitors, e.g., in the event of ICH, but experience is still limited. Methods: This monocentric retrospective observational cohort study included 46 patients with acute FXa-inhibitor-associated non-traumatic ICH (FXa-I-ICH) of whom 23 were treated with AA within 12 h after symptom onset, compared to 23 patients with usual care (UC). Volumetrically analyzed hematoma expansion (HE) in brain imaging, clinical outcome and incidence of adverse events were analyzed. Results: All patients (mean age 79.8 ± 7.2 years) were effectively anticoagulated. The cohort included severely ill patients with large hematoma volumes (median 20.4, IQR 7.8–39.0 mL). Efficacy, as assessed by HE in imaging, was very good in the AA-group. There was no (0.0%) relevant HE (>33%) in contrast to UC-group (26.1%). Nevertheless, we observed a high incidence of thromboembolic events (30.4% vs. 4.4%) and non-favorable outcomes (death/palliative condition) in 43.5% vs. 26.1%. Conclusions: There was no HE in the volumetric neuroimaging assessment in the AA-group, but clinical outcomes remained often worse. Large randomized trials for the use of AA in patients with acute FXa-inhibitor-associated ICH are needed to investigate the clinical outcome in consideration of the rates of thromboembolism. |
format | Online Article Text |
id | pubmed-9224862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92248622022-06-24 Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study Rauch, Sebastian Müller, Hans-Peter Dreyhaupt, Jens Ludolph, Albert C. Kassubek, Jan Althaus, Katharina J Clin Med Article Background: Intracranial hemorrhage (ICH) is associated with high mortality and morbidity, especially in patients under anticoagulative treatment. Andexanet alfa (AA) is a modified recombinant form of human factor Xa (FXa) developed for reversal of FXa-inhibitors, e.g., in the event of ICH, but experience is still limited. Methods: This monocentric retrospective observational cohort study included 46 patients with acute FXa-inhibitor-associated non-traumatic ICH (FXa-I-ICH) of whom 23 were treated with AA within 12 h after symptom onset, compared to 23 patients with usual care (UC). Volumetrically analyzed hematoma expansion (HE) in brain imaging, clinical outcome and incidence of adverse events were analyzed. Results: All patients (mean age 79.8 ± 7.2 years) were effectively anticoagulated. The cohort included severely ill patients with large hematoma volumes (median 20.4, IQR 7.8–39.0 mL). Efficacy, as assessed by HE in imaging, was very good in the AA-group. There was no (0.0%) relevant HE (>33%) in contrast to UC-group (26.1%). Nevertheless, we observed a high incidence of thromboembolic events (30.4% vs. 4.4%) and non-favorable outcomes (death/palliative condition) in 43.5% vs. 26.1%. Conclusions: There was no HE in the volumetric neuroimaging assessment in the AA-group, but clinical outcomes remained often worse. Large randomized trials for the use of AA in patients with acute FXa-inhibitor-associated ICH are needed to investigate the clinical outcome in consideration of the rates of thromboembolism. MDPI 2022-06-13 /pmc/articles/PMC9224862/ /pubmed/35743469 http://dx.doi.org/10.3390/jcm11123399 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rauch, Sebastian Müller, Hans-Peter Dreyhaupt, Jens Ludolph, Albert C. Kassubek, Jan Althaus, Katharina Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title | Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title_full | Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title_fullStr | Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title_full_unstemmed | Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title_short | Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study |
title_sort | andexanet alfa for reversal of factor xa inhibitors in intracranial hemorrhage: observational cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224862/ https://www.ncbi.nlm.nih.gov/pubmed/35743469 http://dx.doi.org/10.3390/jcm11123399 |
work_keys_str_mv | AT rauchsebastian andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy AT mullerhanspeter andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy AT dreyhauptjens andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy AT ludolphalbertc andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy AT kassubekjan andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy AT althauskatharina andexanetalfaforreversaloffactorxainhibitorsinintracranialhemorrhageobservationalcohortstudy |